Medicago successfully produces VLP vaccine candidate for H7N9 virus | Virology News |

Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has successfully produced a new VLP vaccine candidate  for the H7N9 virus that is responsible for the current influenza outbreak in China.

Influenza in birds graphic from Russell Kightley Media